59 related articles for article (PubMed ID: 21666686)
1. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma.
Liu J; Guzman MA; Pezanowski D; Patel D; Hauptman J; Keisling M; Hou SJ; Papenhausen PR; Pascasio JM; Punnett HH; Halligan GE; de Chadarévian JP
Mod Pathol; 2011 Oct; 24(10):1327-35. PubMed ID: 21666686
[TBL] [Abstract][Full Text] [Related]
2. FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma.
de Traux De Wardin H; Cyrta J; Dermawan JK; Guillemot D; Orbach D; Aerts I; Pierron G; Antonescu CR
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23232. PubMed ID: 38607246
[TBL] [Abstract][Full Text] [Related]
3. Adolescent presentation of FGFR1::EBF2 gene fusion mesenchymal tumor.
Jaber O; Sultan I
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23234. PubMed ID: 38593281
[No Abstract] [Full Text] [Related]
4. Role of CD73 and the purinergic signaling pathway in the pathogenesis of fusion-negative rhabdomyosarcoma.
Fascì A; Deaglio S
Purinergic Signal; 2024 May; ():. PubMed ID: 38700722
[No Abstract] [Full Text] [Related]
5. Developing cancer therapies - think global.
Hollenbach AD
Aging (Albany NY); 2016 Nov; 8(11):2605-2606. PubMed ID: 27852978
[No Abstract] [Full Text] [Related]
6. Classification of rhabdomyosarcoma and its molecular basis.
Parham DM; Barr FG
Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309
[TBL] [Abstract][Full Text] [Related]
7. Transforming fusions of FGFR and TACC genes in human glioblastoma.
Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
[TBL] [Abstract][Full Text] [Related]
8. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
[TBL] [Abstract][Full Text] [Related]
9. RNASeq Analysis for Accurate Identification of Fusion Partners in Tumor Specific Translocations Detected by Standard FISH Probes in Hematologic Malignancies.
Koduru P; Chen W; Fuda F; Kaur G; Awan F; John S; Garcia R; Gagan J
Clin Pathol; 2024; 17():2632010X241230262. PubMed ID: 38371338
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.
Chehelgerdi M; Chehelgerdi M; Khorramian-Ghahfarokhi M; Shafieizadeh M; Mahmoudi E; Eskandari F; Rashidi M; Arshi A; Mokhtari-Farsani A
Mol Cancer; 2024 Jan; 23(1):9. PubMed ID: 38195537
[TBL] [Abstract][Full Text] [Related]
11. Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers.
Brown LM; Ekert PG; Fleuren EDG
Oncogene; 2023 Jun; 42(23):1875-1888. PubMed ID: 37130917
[TBL] [Abstract][Full Text] [Related]
12. CD147 Promotes Tumorigenesis via Exosome-Mediated Signaling in Rhabdomyosarcoma.
Fahs A; Hussein N; Zalzali H; Ramadan F; Ghamloush F; Tamim H; El Homsi M; Badran B; Boulos F; Tawil A; Ghayad SE; Saab R
Cells; 2022 Jul; 11(15):. PubMed ID: 35892564
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of gene fusions in soft tissue sarcomas by Ion AmpliSeq
Wei R; Gao F; Zeng Z; Gui Z; Shang Y; Shen N; Wang Z; Han W; Shen H; Li X; E L; Ma W; Wang C
Transl Cancer Res; 2022 Mar; 11(3):488-499. PubMed ID: 35402176
[TBL] [Abstract][Full Text] [Related]
14. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
Napolitano A; Ostler AE; Jones RL; Huang PH
Cells; 2021 Jun; 10(6):. PubMed ID: 34204560
[TBL] [Abstract][Full Text] [Related]
16. Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.
Acosta AM; Sholl LM; Dickson BC; McKenney JK; Gordetsky JB; Pins MR; Marino-Enriquez A; Dong F; Dubuc AM; Cin PD; Fletcher CDM
Mod Pathol; 2021 Sep; 34(9):1763-1779. PubMed ID: 33986460
[TBL] [Abstract][Full Text] [Related]
17. Soft Tissue Special Issue: Skeletal Muscle Tumors: A Clinicopathological Review.
Kohashi K; Kinoshita I; Oda Y
Head Neck Pathol; 2020 Mar; 14(1):12-20. PubMed ID: 31950473
[TBL] [Abstract][Full Text] [Related]
18. The current landscape of rhabdomyosarcomas: an update.
Leiner J; Le Loarer F
Virchows Arch; 2020 Jan; 476(1):97-108. PubMed ID: 31696361
[TBL] [Abstract][Full Text] [Related]
19. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
20. Unusual Signal Patterns of Break-apart FISH Probes Used in the Diagnosis of Soft Tissue Sarcomas.
Papp G; Mihály D; Sápi Z
Pathol Oncol Res; 2017 Oct; 23(4):863-871. PubMed ID: 28108880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
